Paper Details

  1. Home
  2. Paper Details

Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis: a systematic review and economic evaluation.

Author: AbramsK, BojkeL, BruceI, BujkiewiczS, ChalmersR, CooperN, CraigD, EpsteinD, FonsecaT, LaiM, MyersL, RodgersM, SculpherM, SpiegelhalterD, SuttonA, WoolacottN, YangH

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.
Systematic ReviewA review that systematically collects, evaluates, and integrates relevant research to answer a specific research question.

Overview

Etanercept, infliximab, and adalimumab were effective in treating psoriatic arthritis (PsA) compared to placebo, with improvements in joint symptoms, functional status, and skin. Etanercept was the most cost-effective option for patients with mild-to-moderate psoriasis.
Paper Details　
Original Abstract of the Article :
BACKGROUND: Etanercept, infliximab and adalimumab are licensed in the UK for the treatment of active and progressive psoriatic arthritis (PsA) in adults who have an inadequate response to standard treatment. OBJECTIVE: To determine the clinical effectiveness, safety and cost-effectiveness of these ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4781419/

データ提供：米国国立医学図書館（NLM）

Treating Psoriatic Arthritis: Navigating the Desert of Treatment Options

Psoriatic arthritis, a chronic inflammatory disease, is like a desert storm, wreaking havoc on joints and skin. This research explores the effectiveness and cost-effectiveness of three biologic agents—etanercept, infliximab, and adalimumab—as potential oases of relief in this challenging landscape.

Biologic Agents: Oasis of Relief

The study reveals that these biologic agents significantly improve joint disease, functional status, and skin lesions. These agents act like life-giving water in the desert, providing relief and improving quality of life.

Cost-Effectiveness: Finding the Right Oasis

The study also delves into the economic aspects of treatment, analyzing the cost-effectiveness of each agent. This is akin to a desert traveler choosing the most efficient route to reach a vital oasis.

Dr. Camel's Conclusion

Psoriatic arthritis presents a formidable challenge, but this research offers valuable insights into the potential benefits of biologic agents. Finding the right treatment, like locating a refreshing oasis in the desert, is crucial for patients seeking relief and improved quality of life.

Date :
  1. Date Completed 2011-06-24
  2. Date Revised 2022-04-08
Further Info :

Pubmed ID

21333232

DOI: Digital Object Identifier

PMC4781419

Related Literature

Article Analysis
・Effective treatment of psoriatic arthritis
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.